Skip to main content
. 2005 Sep 20;93(9):1046–1052. doi: 10.1038/sj.bjc.6602787

Table 3. Relationship between breast cancer histology and tumour stage, hormone receptor status, and grade among women diagnosed at 30–49 years of agea.

  Ductal (n=27 665) Lobular (n=1888)
Ductal/lobular (n=2277)
Mucinous (n=518)
Comedo (n=850)
Tumour characteristic % % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI
Stage b
 I 40 36 1.0 ref 36 1.0 ref 61 1.0 ref 42 1.0 ref
 II 50 48 1.2 1.1–1.4† 52 1.3 1.2–1.4† 35 0.5 0.4–0.6† 49 0.8 0.7–1.0†
 III/IV 10 16 2.4 2.1–2.7† 12 1.7 1.5–1.9† 4 0.3 0.2–0.5† 9 0.7 0.6–1.0†
 
Tumour size (cm) b
 <2.0 49 43 1.0 ref 48 1.0 ref 59 1.0 ref 48 1.0 ref
 2.0–4.9 42 39 1.3 1.2–1.4† 40 1.1 1.0–1.2† 34 0.8 0.6–0.9† 41 0.9 0.8–1.0
 ⩾5.0 9 18 3.4 2.9–3.9† 12 1.8 1.6–2.2† 7 0.8 0.5–1.1 12 1.2 0.9–1.5
 
Lymph node status b
 Negative 57 54 1.0 ref 48 1.0 ref 85 1.0 ref 60 1.0 ref
 Positive 43 46 1.2 1.1–1.3† 52 1.4 1.3–1.6† 15 0.2 0.2–0.3† 40 0.8 0.7–1.0†
 
ER c
 ER+ 66 89 1.0 ref 87 1.0 ref 91 1.0 ref 56 1.0 ref
 ER− 34 11 0.4 0.3–0.5† 13 0.4 0.4–0.5† 9 0.2 0.1–0.3† 44 1.2 1.0–1.5
 
PR c
 PR+ 63 85 1.0 ref 83 1.0 ref 81 1.0 ref 54 1.0 ref
 PR− 38 15 0.5 0.5–0.6† 17 0.6 0.5–0.7† 19 1.1 0.8–1.4 46 1.3 1.0–1.5†
 
ER/PR c
 ER+/PR+ 58 81 1.0 ref 80 1.0 ref 79 1.0 ref 46 1.0 ref
 ER+/PR− 8 8 0.7 0.6–0.8† 8 0.6 0.5–0.8† 12 1.1 0.9–1.5 11 1.6 1.2–2.0†
 ER−/PR+ 5 4 0.6 0.5–0.8† 3 0.5 0.4–0.7† 2 0.3 0.2–0.6† 8 1.6 1.2–2.1†
 ER−/PR− 29 7 0.2 0.1–0.2† 10 0.2 0.2–0.3† 7 0.2 0.1–0.3† 36 1.5 1.3–1.7†
 
Grade d
 1 10 19 1.0 ref 14 1.0 ref 45 1.0 ref 4 1.0 ref
 2 37 55 0.8 0.7–0.9† 51 1.0 0.9–1.1 41 0.3 0.2–0.4† 28 1.7 1.1–2.6†
 3 50 22 0.3 0.3–0.4† 32 0.6 0.5–0.7† 13 0.1 0.1–0.1† 57 2.5 1.7–3.8†
 4 3 3 0.7 0.5–1.0 3 0.9 0.7–1.2 1 0.1 0.03–0.3† 11 7.2 4.5–11.7†
  Inflammatory (n=708)
Tubular (n=386)
Medullary (n=746)
Papillary (n=91)
  % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI
Stage b
 I 0 N/Ae   87 1.0 ref 33 1.0 ref 42 1.0 ref
 II 1     12 0.1 0.1–0.2† 62 1.1 0.9–1.3 50 0.9 0.6–1.5
 III/IV 99     1 0.03 0.01–0.1† 4 0.3 0.2–0.5† 9 0.8 0.4–1.8
 
Tumour size (cm) b
 <2.0 2 N/Ae   92 1.0 ref 34 1.0 ref 52 ref  
 2.0–4.9 7     7 0.1 0.1–0.2† 60 1.4 1.2–1.7† 36 0.8  
 ⩾5.0 91     1 0.1 0.03–0.2† 6 0.6 0.4–0.8† 12 1.4  
 
Lymph node status b
 Negative 9 1.0 ref 91 1.0 ref 69 1.0 ref 59 1.0 ref
 Positive 91 12.7 9.0–17.8† 9 0.1 0.1–0.2† 31 0.6 0.5–0.7† 41 0.9 0.6–1.4
 
ER c
 ER+ 43 1.0 ref 93 1.0 ref 14 1.0 ref 77 1.0 ref
 ER− 57 1.7 1.4–2.2† 8 0.2 0.2–0.4† 86 5.8 4.4–7.6† 23 0.7 0.4–1.4
 
PR c
 PR+ 41 1.0 ref 85 1.0 ref 16 1.0 ref 75 1.0 ref
 PR− 60 1.1 0.9–1.4 15 0.8 0.6–1.1 84 2.5 2.0–3.2† 25 0.7 0.4–1.3
 
ER/PR c
 ER+/PR+ 34 1.0 ref 82 1.0 ref 10 1.0 ref 70 1.0 ref
 ER+/PR− 9 1.2 0.9–1.6 10 1.0 0.7–1.4 4 3.2 2.1–4.8† 7 0.6 0.3–1.5
 ER-/PR+ 7 1.9 1.3–2.7† 3 0.5 0.3–1.0† 7 7.1 4.9–10.3† 4 0.7 0.2–1.9
 ER−/PR− 50 1.9 1.6–2.3† 5 0.2 0.1–0.3† 80 15.3 11.9–19.6† 19 0.5 0.3–0.9†
 
Grade d
 1 1 1.0 ref 87 N/Ae   1 N/Ae   22 1.0 ref
 2 20 2.2 1.0–4.9† 12     6     49 0.6 0.3–1.1
 3 72 2.7 1.3–5.9† 1     81     23 0.2 0.1–0.5†
 4 6 2.8 1.2–6.7† 0     1     6 0.9 0.3–2.9

OR=odds ratio, CI=confidence interval, ER=oestrogen receptor, PR=progesterone receptor, N/A=not applicable.

†

P<0.05.

a

The reference histologic type for all analyses was ductal carcinoma.

b

ORs are adjusted for age and year at diagnosis, cancer registry, race/ethnicity, and ER/PR status. Data on tumour size missing for 209 ductal, 24 lobular, 17 ductal/lobular, three mucinous, five comedo, 36 inflammatory, and one papillary carcinomas. Data on lymph node status missing for 1242 ductal, 118 lobular, 87 ductal/lobular, 28 mucinous, 54 comedo, 26 tubular, 17 medullary, 304 inflammatory, and six papillary carcinomas.

c

ORs are adjusted for age and year at diagnosis, cancer registry, race/ethnicity, and stage. In addition, ORs for ER status are adjusted for PR status, and ORs for PR status are adjusted for ER status.

d

ORs are adjusted for age and year at diagnosis, cancer registry, race/ethnicity, stage, and ER/PR status. Data on grade missing for 1732 ductal, 794 lobular, 289 ductal/lobular, 198 mucinous, 215 comedo, 75 tubular, 251 medullary, 102 inflammatory, and 22 papillary carcinomas.

e

These ORs were not calculated because almost all inflammatory carcinomas are stage III or IV and greater than 5.0 cm in size, almost all tubular carcinomas are well differentiated, and almost all medullary carcinomas are poorly differentiated.